The gross proceeds to Cidara from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $350.0 million. In addition, Cidara has granted the ...

Houston, TX, June 24, 2025 (GLOBE NEWSWIRE) -- Shiny Smile Veneers, a US-based provider of custom-made snap-on veneers, has ...

In connection with the offering, the Company issued 1,180,877 shares of common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) at a purchase price of $3.60 per share, ...

Corbus Fireside Chat June 26, 2025, 10:00 a.m. ET Hosted by Biren Amin, Managing Director Pipe Sandler - Healthcare Equity Research ...

Abvance Therapeutics, a biotechnology company developing next-generation glucagon analogs and therapies to prevent hypoglycemia and improve glucose management, today announced the closing of its ...

Revuforj (revumenib) is an oral, first-in-class, selective menin inhibitor that is FDA approved for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene ...

Decision at the highest levels of appeal in the Medicare process establishes medical necessity of the ReWalk Exoskeleton for enabling paralyzed individuals to stand and walk in everyday environments.

Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF), one of the fastest-growing, vertically integrated cannabis companies in ...

NeuroPace is pleased to have a financial leader of Patrick’s caliber join the team at a time of such significant opportunity for our RNS System and critical point in our growth trajectory,” said Joel ...

The re-election of Mr. Craig Collard, Ms. Ira Duarte, Mr. Ed Schutter, Ms. Kara DioGuardi and Mr. Jason Wild as directors of the Company for the ensuing year, the voting results of which are as ...

The Reverse Share Split was approved by the Company’s shareholders at the Company’s Annual General Meeting of Shareholders held on October 23, 2024, to be effected at the board of directors’ ...

(the “Company”) (Nasdaq: NSPR), developer of the CGuard Prime Carotid Stent System for the prevention of stroke, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket ...